# Aware Inc: financial statements, quarterly

AWRE · Nasdaq · CIK 1015739 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/awre.md) · [Financials](/companies/awre/financials.md) · [Filings](/companies/awre/filings.md) · [Insiders](/companies/awre/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/awre/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6,381](/filings/0000950170-24-120107.md) | [4,374 d](/filings/0000950170-25-038714.md) | [4,421](/filings/0000950170-25-062767.md) | [4,322](/filings/0000950170-25-101395.md) | [3,849](/filings/0001193125-25-260701.md) | [4,797 d](/filings/0001193125-26-096448.md) | [3,608](/filings/0001193125-26-201370.md) | [3,895](/filings/0001193125-26-328344.md) | [5,129](/filings/0001193125-25-260701.md) | [4,662 d](/filings/0001193125-26-096448.md) | [3,386](/filings/0001193125-26-201370.md) | [3,254](/filings/0001193125-26-328344.md) |
| Cost of revenue | $k | [410](/filings/0000950170-24-120107.md) | [240 d](/filings/0000950170-25-038714.md) | [276](/filings/0000950170-25-062767.md) | [270](/filings/0000950170-25-101395.md) | [270](/filings/0001193125-25-260701.md) | [18.0 d](/filings/0001193125-26-096448.md) | [173](/filings/0001193125-26-201370.md) | [267](/filings/0001193125-26-328344.md) | [491](/filings/0001193125-25-260701.md) | [248 d](/filings/0001193125-26-096448.md) | [334](/filings/0001193125-26-201370.md) | [520](/filings/0001193125-26-328344.md) |
| Research and development | $k | [2,264](/filings/0000950170-24-120107.md) | [2,215 d](/filings/0000950170-25-038714.md) | [2,182](/filings/0000950170-25-062767.md) | [1,867](/filings/0000950170-25-101395.md) | [1,873](/filings/0001193125-25-260701.md) | [1,835 d](/filings/0001193125-26-096448.md) | [1,922](/filings/0001193125-26-201370.md) | [1,960](/filings/0001193125-26-328344.md) | [2,131](/filings/0001193125-25-260701.md) | [2,287 d](/filings/0001193125-26-096448.md) | [3,223](/filings/0001193125-26-201370.md) | [2,533](/filings/0001193125-26-328344.md) |
| Operating income | $k | [747](/filings/0000950170-24-120107.md) | [(4,483) d](/filings/0000950170-25-038714.md) | [(1,262)](/filings/0000950170-25-062767.md) | [(1,341)](/filings/0000950170-25-101395.md) | [(1,467)](/filings/0001193125-25-260701.md) | [(1,474) d](/filings/0001193125-26-096448.md) | [(1,852)](/filings/0001193125-26-201370.md) | [(1,961)](/filings/0001193125-26-328344.md) | [(1,295)](/filings/0001193125-25-260701.md) | [(1,452) d](/filings/0001193125-26-096448.md) | [(3,650)](/filings/0001193125-26-201370.md) | [(2,739)](/filings/0001193125-26-328344.md) |
| Income tax | $k | [0.0](/filings/0000950170-23-058837.md) | [59.0 d](/filings/0000950170-25-038714.md) | [0.0](/filings/0000950170-25-062767.md) | [39.0](/filings/0000950170-25-101395.md) | [15.0](/filings/0001193125-25-260701.md) | [(1.0) d](/filings/0001193125-26-096448.md) | [7.0](/filings/0001193125-26-201370.md) | [26.0](/filings/0001193125-26-328344.md) | [5.0](/filings/0001193125-25-260701.md) | [219 d](/filings/0001193125-26-096448.md) | [8.0](/filings/0001193125-26-201370.md) | [1.0](/filings/0001193125-26-328344.md) |
| Net income | $k | [1,144](/filings/0000950170-24-120107.md) | [(4,239) d](/filings/0000950170-25-038714.md) | [(982)](/filings/0001193125-25-260701.md) | [(1,090)](/filings/0001193125-25-260701.md) | [(1,167)](/filings/0001193125-25-260701.md) | [(1,192) d](/filings/0001193125-26-096448.md) | [(1,598)](/filings/0001193125-26-328344.md) | [(1,769)](/filings/0001193125-26-328344.md) | [(1,053)](/filings/0001193125-25-260701.md) | [(1,456) d](/filings/0001193125-26-096448.md) | [(3,458)](/filings/0001193125-26-328344.md) | [(2,565)](/filings/0001193125-26-328344.md) |
| Diluted EPS | $ per share | [0.05](/filings/0000950170-24-120107.md) | not reported | [(0.05)](/filings/0000950170-25-062767.md) | [(0.05)](/filings/0000950170-25-101395.md) | [(0.06)](/filings/0001193125-25-260701.md) | not reported | [(0.08)](/filings/0001193125-26-201370.md) | [(0.08)](/filings/0001193125-26-328344.md) | [(0.05)](/filings/0001193125-25-260701.md) | not reported | [(0.16)](/filings/0001193125-26-201370.md) | [(0.12)](/filings/0001193125-26-328344.md) |
| Basic EPS | $ per share | [0.05](/filings/0000950170-24-120107.md) | not reported | [(0.05)](/filings/0000950170-25-062767.md) | [(0.05)](/filings/0000950170-25-101395.md) | [(0.06)](/filings/0001193125-25-260701.md) | not reported | [(0.08)](/filings/0001193125-26-201370.md) | [(0.08)](/filings/0001193125-26-328344.md) | [(0.05)](/filings/0001193125-25-260701.md) | not reported | [(0.16)](/filings/0001193125-26-201370.md) | [(0.12)](/filings/0001193125-26-328344.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.7](/filings/0000950170-23-058837.md) | [10.0](/filings/0000950170-25-038714.md) | [14.3](/filings/0000950170-24-052854.md) | [11.5](/filings/0000950170-24-094716.md) | [11.2](/filings/0000950170-24-120107.md) | [13.0](/filings/0001193125-26-096448.md) | [8.5](/filings/0000950170-25-062767.md) | [7.3](/filings/0000950170-25-101395.md) | [6.3](/filings/0001193125-25-260701.md) | [7.3](/filings/0001193125-26-328344.md) | [4.6](/filings/0001193125-26-201370.md) | [2.9](/filings/0001193125-26-328344.md) |
| Current assets | $m | [36.8](/filings/0000950170-23-058837.md) | [35.8](/filings/0000950170-25-038714.md) | [34.8](/filings/0000950170-24-052854.md) | [33.1](/filings/0000950170-24-094716.md) | [33.8](/filings/0000950170-24-120107.md) | [33.0](/filings/0001193125-26-096448.md) | [30.4](/filings/0000950170-25-062767.md) | [28.8](/filings/0000950170-25-101395.md) | [31.2](/filings/0001193125-25-260701.md) | [28.3](/filings/0001193125-26-328344.md) | [24.5](/filings/0001193125-26-201370.md) | [21.1](/filings/0001193125-26-328344.md) |
| Total assets | $m | [50.2](/filings/0000950170-23-058837.md) | [46.3](/filings/0000950170-25-038714.md) | [45.1](/filings/0000950170-24-052854.md) | [43.2](/filings/0000950170-24-094716.md) | [43.7](/filings/0000950170-24-120107.md) | [42.6](/filings/0001193125-26-096448.md) | [39.9](/filings/0000950170-25-062767.md) | [38.1](/filings/0000950170-25-101395.md) | [40.3](/filings/0001193125-25-260701.md) | [37.2](/filings/0001193125-26-328344.md) | [33.2](/filings/0001193125-26-201370.md) | [29.6](/filings/0001193125-26-328344.md) |
| Current liabilities | $m | [7.9](/filings/0000950170-23-058837.md) | [7.5](/filings/0000950170-25-038714.md) | [7.4](/filings/0000950170-24-052854.md) | [6.5](/filings/0000950170-24-094716.md) | [7.8](/filings/0000950170-24-120107.md) | [7.9](/filings/0001193125-26-096448.md) | [6.6](/filings/0000950170-25-062767.md) | [6.3](/filings/0000950170-25-101395.md) | [9.3](/filings/0001193125-25-260701.md) | [7.5](/filings/0001193125-26-328344.md) | [6.9](/filings/0001193125-26-201370.md) | [5.7](/filings/0001193125-26-328344.md) |
| Shareholders' equity | $m | [37.9](/filings/0000950170-24-120107.md) | [34.3](/filings/0001193125-26-096448.md) | [33.4](/filings/0001193125-25-260701.md) | [32.6](/filings/0001193125-25-260701.md) | [31.9](/filings/0001193125-25-260701.md) | [30.9](/filings/0001193125-26-328344.md) | [29.5](/filings/0001193125-26-328344.md) | [28.1](/filings/0001193125-26-328344.md) | [27.2](/filings/0001193125-25-260701.md) | [26.1](/filings/0001193125-26-328344.md) | [22.9](/filings/0001193125-26-328344.md) | [20.6](/filings/0001193125-26-328344.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [2,457 d](/filings/0000950170-24-120107.md) | [3,065 d](/filings/0000950170-25-038714.md) | [(2,411)](/filings/0000950170-25-062767.md) | [(668) d](/filings/0000950170-25-101395.md) | [(765) d](/filings/0001193125-25-260701.md) | [683 d](/filings/0001193125-26-096448.md) | [(2,940)](/filings/0001193125-26-201370.md) | [(1,151) d](/filings/0001193125-26-328344.md) | [(2,353) d](/filings/0001193125-25-260701.md) | [1,046 d](/filings/0001193125-26-096448.md) | [(2,677)](/filings/0001193125-26-201370.md) | [(2,764) d](/filings/0001193125-26-328344.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-120107.md) | [0.0 d](/filings/0000950170-25-038714.md) | not reported | not reported | [0.0 d](/filings/0001193125-25-260701.md) | [0.0 d](/filings/0001193125-26-096448.md) | [45.0](/filings/0001193125-26-201370.md) | [0.0 d](/filings/0001193125-26-328344.md) | [0.0 d](/filings/0001193125-25-260701.md) | [120 d](/filings/0001193125-26-096448.md) | [0.0](/filings/0001193125-26-201370.md) | [0.0 d](/filings/0001193125-26-328344.md) |
| Dividends paid | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | [126 d](/filings/0000950170-24-120107.md) | [39.0 d](/filings/0000950170-25-038714.md) | not reported | not reported | not reported | not reported | [53.0](/filings/0001193125-26-201370.md) | [62.0 d](/filings/0001193125-26-328344.md) | [0.0 d](/filings/0001193125-25-260701.md) | [0.0 d](/filings/0001193125-26-096448.md) | [0.0](/filings/0001193125-26-201370.md) | [0.0 d](/filings/0001193125-26-328344.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [21.8](/filings/0000950170-23-058837.md) | [21.0](/filings/0000950170-24-052854.md) | [21.0](/filings/0000950170-24-094716.md) | [21.1](/filings/0000950170-24-120107.md) | [21.1](/filings/0000950170-25-062767.md) | [21.1](/filings/0000950170-25-101395.md) | [21.2](/filings/0001193125-25-260701.md) | [21.3](/filings/0001193125-26-201370.md) | [21.3](/filings/0001193125-26-328344.md) | [21.2](/filings/0001193125-25-260701.md) | [21.6](/filings/0001193125-26-201370.md) | [21.7](/filings/0001193125-26-328344.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 21,812,637 at 2026-07-27, from the cover of the [10-Q filed 2026-07-31](/filings/0001193125-26-328344.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:30 ET. No prices; not investment advice.